Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached "critical mass" in its efforts to diversify into oncology and inflammation, CEO Daniel O'Day told Fierce.
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached "critical mass" in its efforts to diversify into oncology and inflammation, CEO...
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached "critical mass" in its efforts to diversify into oncology and inflammation, CEO Daniel O'Day told Fierce.
Open the app view to save this story, compare related coverage, and continue from the same source.